53,317 Shares in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. acquired a new stake in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) during the first quarter, Holdings Channel reports. The firm acquired 53,317 shares of the company’s stock, valued at approximately $1,184,000.

Other institutional investors also recently added to or reduced their stakes in the company. GAMMA Investing LLC boosted its holdings in Kiniksa Pharmaceuticals International by 84.8% during the first quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock valued at $27,000 after purchasing an additional 568 shares in the last quarter. Asset Management One Co. Ltd. acquired a new stake in Kiniksa Pharmaceuticals International during the first quarter valued at approximately $41,000. Wealthquest Corp bought a new position in shares of Kiniksa Pharmaceuticals International in the first quarter valued at approximately $42,000. Lazard Asset Management LLC bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $61,000. Finally, KLP Kapitalforvaltning AS bought a new position in shares of Kiniksa Pharmaceuticals International in the fourth quarter valued at approximately $158,000. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $30.06 on Thursday. The company has a 50 day moving average price of $28.19 and a 200 day moving average price of $23.89. Kiniksa Pharmaceuticals International, plc has a fifty-two week low of $17.82 and a fifty-two week high of $31.92. The stock has a market capitalization of $2.19 billion, a PE ratio of 751.69 and a beta of 0.05.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.08%. The firm had revenue of $156.80 million during the quarter, compared to analysts’ expectations of $145.21 million. As a group, equities analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 earnings per share for the current fiscal year.

Insider Transactions at Kiniksa Pharmaceuticals International

In related news, CFO Mark Ragosa sold 18,299 shares of the business’s stock in a transaction that occurred on Tuesday, June 3rd. The shares were sold at an average price of $28.80, for a total value of $527,011.20. Following the completion of the transaction, the chief financial officer owned 27,009 shares in the company, valued at $777,859.20. The trade was a 40.39% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CAO Michael R. Megna sold 17,647 shares of the business’s stock in a transaction that occurred on Wednesday, May 7th. The stock was sold at an average price of $26.69, for a total transaction of $470,998.43. Following the completion of the transaction, the chief accounting officer owned 32,546 shares of the company’s stock, valued at $868,652.74. This trade represents a 35.16% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 320,981 shares of company stock worth $9,189,467 over the last ninety days. 53.48% of the stock is currently owned by insiders.

Analyst Ratings Changes

KNSA has been the subject of a number of research analyst reports. Jefferies Financial Group lifted their target price on shares of Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a research note on Tuesday. Wall Street Zen upgraded shares of Kiniksa Pharmaceuticals International from a “hold” rating to a “buy” rating in a research note on Sunday, July 6th. Wells Fargo & Company lifted their target price on shares of Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an “overweight” rating in a research note on Wednesday, July 9th. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 target price on shares of Kiniksa Pharmaceuticals International in a research note on Monday, July 21st. Seven investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $41.17.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.